High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy
Key facts
- Who runs it
- Sung-Han Kim
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 2 Nov 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- High-dose inactivated influenza vaccine
- Standard-dose inactivated influenza vaccine
- Record updated
- 9 November 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 19 years or older
- Confirmed diagnosis of hematologic malignancy
- Has received B-cell-depleting therapy (anti-CD20 antibody, bispecific antibody, or CAR-T cell therapy) within 2 years before vaccination
- Able and willing to provide written informed consent and comply with study procedures
Who cannot take part
- Known hypersensitivity to influenza vaccine components
- Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)
- Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures
- Any other condition deemed clinically inappropriate for study participation at investigator discretion
- Influenza vaccination within the preceding 6 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized trial will compare the immune responses to high-dose and standard-dose influenza vaccines in 60 adults with blood cancers (hematologic malignancies) who have received B-cell-depleting therapy. Participants will be assigned by chance, in a 1:1 ratio, to receive one of the two vaccines. Antibody and T-cell responses will be measured before and after vaccination. Participants and their treating clinicians will know which vaccine is given. Laboratory staff who measure and interpret the immune responses will not know which vaccine each participant received until the laboratory results are finalized.
The 2 groups in the trial
- High dose influenza vaccineTreatment being tested
Participants receive a single intramuscular dose of high-dose trivalent inactivated influenza vaccine (Efluelda), containing 60 micrograms of hemagglutinin per strain, on Day 0.
Treatment: High-dose inactivated influenza vaccine
- Standard-Dose Influenza VaccineExisting treatment, for comparison
Participants receive a single intramuscular dose of standard-dose trivalent inactivated influenza vaccine, containing 15 micrograms of hemagglutinin per strain, on Day 0.
Treatment: Standard-dose inactivated influenza vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunogenicity of High-Dose Versus Standard-Dose Inactivated Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy: A Randomized Trial With Blinded Laboratory Outcome Assessment
- Record updated
- 9 November 2026